AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10629434 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined challenge tests (D-FEN and IPS)
Number of subjects: 16
Study 8997012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate suspension
Number of subjects: 0
Study 8997012 — intervention group
Group type: COMPARATOR
Intervention: Antacid suspension
Number of subjects: 0
Study 7956716 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl APD (3‐dimethylamino‐1‐hydroxypropylidene‐1, 1‐bisphosphonate) at doses of 50, 100, 200, and 400 mg
Number of subjects: 0
Study 7956716 — intervention group
Group type: COMPARATOR
Intervention: Pamidronate (3‐amino‐1‐hydroxypropylidene‐1, 1‐bisphosphonate) at doses of 300, 600, and 900 mg
Number of subjects: 0
Study 2434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 1.25 mg
Number of subjects: 12
Study 2434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg
Number of subjects: 12
Study 2434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 5 mg
Number of subjects: 12
Study 2434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril 10 mg
Number of subjects: 12
Study 2434791 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilazapril
Number of subjects: 12
Study 31286913 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens with capsular tension ring (CTR)
Number of subjects: 179
Study 31286913 — intervention group
Group type: COMPARATOR
Intervention: Toric intraocular lens without capsular tension ring (CTR)
Number of subjects: 179
Study 31286913 — intervention group
Group type: EXPERIMENTAL
Intervention: Toric intraocular lens (overall sample)
Number of subjects: 179
Study 27333127 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized symptom management strategies for CRF
Number of subjects: 47
Study 28240566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptive randomization treatment regimens
Number of subjects: 750
Study 28240566 — intervention group
Group type: COMPARATOR
Intervention: Bayesian adaptive randomization
Number of subjects: 750
Study 23826760 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of oral sodium bicarbonate with a serum target HCO3- level of 24±1 mmol/L
Number of subjects: 200
Study 23826760 — intervention group
Group type: COMPARATOR
Intervention: Rescue therapy of sodium bicarbonate with a serum target level of 20±1 mmol/L
Number of subjects: 200
Study 23826760 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of oral sodium bicarbonate
Number of subjects: 200
Study 23826760 — intervention group
Group type: COMPARATOR
Intervention: Rescue therapy of sodium bicarbonate
Number of subjects: 200
Study 21839405 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and high-dose dexamethasone (Len+Dex)
Number of subjects: 0
Study 21839405 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone alone (Dex)
Number of subjects: 0
Study 19259967 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate
Number of subjects: 50
Study 19259967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16877721 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEndostatin administered as a bid subcutaneous injection at a starting dose of 60 mg/m2/d, escalated to 90 mg/m2/d if necessary
Number of subjects: 42
Study 15265253 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 151
Study 15265253 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 151
Study 15265253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 11386930 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alpha‐gal A (0.2 mg/kg every other week for 12 doses)
Number of subjects: 26
Study 11386930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 8928459 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-examination group
Number of subjects: 122471
Study 8928459 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 122471
Study 8928459 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 122471
Study 8928459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 50-59
Number of subjects: 122471
Study 1985618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular methylprednisolone and lidocaine
Number of subjects: 48
Study 1985618 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrabursal methylprednisolone and lidocaine
Number of subjects: 48
Study 1985618 — intervention group
Group type: COMPARATOR
Intervention: Intra-articular lidocaine
Number of subjects: 48
Study 1985618 — intervention group
Group type: COMPARATOR
Intervention: Intrabursal lidocaine
Number of subjects: 48
Study 6403000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin base plus parenteral placebo
Number of subjects: 1128
Study 6403000 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and erythromycin base plus parenteral cephalothin sodium
Number of subjects: 1128
Study 30738199 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-life care simulation with standardized patients
Number of subjects: 38
Study 30738199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no simulation)
Number of subjects: 38
Study 28283937 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment initiated at 2 weeks after hemiarthroplasty
Number of subjects: 100
Study 28283937 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonate treatment initiated at 12 weeks after hemiarthroplasty
Number of subjects: 100
Study 26374766 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (ACh)
Number of subjects: 119
Study 26374766 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 119
Study 26374766 — intervention group
Group type: EXPERIMENTAL
Intervention: BQ-123 (ETA receptor blocker)
Number of subjects: 119
Study 23968656 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 0.375% ropivacaine combined with 1 μg kg(‐1) of dexmedetomidine
Number of subjects: 40
Study 23968656 — intervention group
Group type: COMPARATOR
Intervention: 30 mL of 0.375% ropivacaine combined with saline (control)
Number of subjects: 40
Study 21270672 — intervention group
Group type: EXPERIMENTAL
Intervention: Boston EO lenses (Dk/t: 26)
Number of subjects: 11
Study 21270672 — intervention group
Group type: COMPARATOR
Intervention: Boston XO lenses (Dk/t: 46)
Number of subjects: 11
Study 21270672 — intervention group
Group type: EXPERIMENTAL
Intervention: Both lens materials
Number of subjects: 11
Study 19470152 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Scalpel (H)
Number of subjects: 0
Study 19470152 — intervention group
Group type: COMPARATOR
Intervention: Monopolar Diathermy (M)
Number of subjects: 0
Study 17370498 — intervention group
Group type: EXPERIMENTAL
Intervention: Uylabris
Number of subjects: 175
Study 17370498 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeds of Brassica Alb (0.05 g each point)
Number of subjects: 175
Study 17370498 — intervention group
Group type: EXPERIMENTAL
Intervention: Seeds of Brassica Alb (0.01 g each point)
Number of subjects: 175
Study 15342211 — intervention group
Group type: EXPERIMENTAL
Intervention: TAFI antigen levels in patients with preeclampsia
Number of subjects: 60
Study 15342211 — intervention group
Group type: COMPARATOR
Intervention: TAFI antigen levels in normal pregnant women (control)
Number of subjects: 60
Study 15342211 — intervention group
Group type: COMPARATOR
Intervention: Comparison of TAFI antigen levels between preeclamptic patients and normal pregnant women
Number of subjects: 60
Study 11133625 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 50
Study 11133625 — intervention group
Group type: COMPARATOR
Intervention: Control Group (sterile water)
Number of subjects: 50
Study 9772137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet with 15% of energy as protein
Number of subjects: 69
Study 9772137 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein (SP) diet with 7.5% energy as protein
Number of subjects: 69
Study 9772137 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein (HP) diet
Number of subjects: 69
Study 9772137 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein (SP) diet
Number of subjects: 69
Study 7598068 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary supplementation with > or = 10 g n-3 fatty acids from fish oil for > 12 months
Number of subjects: 0
Study 7598068 — intervention group
Group type: COMPARATOR
Intervention: Nonsupplemented control subjects
Number of subjects: 0
Study 7598068 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined values for all subjects
Number of subjects: 0
Study 2911877 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine position with 1 mg bumethanide intravenously
Number of subjects: 12
Study 2911877 — intervention group
Group type: COMPARATOR
Intervention: Upright position with 1 mg bumethanide intravenously
Number of subjects: 12
Study 1099898 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid
Number of subjects: 28
Study 1099898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1099898 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 31417013 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted antibiotics (TA) based on rectal swab culture
Number of subjects: 100
Study 31417013 — intervention group
Group type: COMPARATOR
Intervention: Empirical antibiotics (EA) - standard parenteral ciprofloxacin
Number of subjects: 100
Study 31417013 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TA and EA
Number of subjects: 100
Study 28099054 — intervention group
Group type: EXPERIMENTAL
Intervention: Full Code
Number of subjects: 533
Study 28099054 — intervention group
Group type: COMPARATOR
Intervention: DNR/DNI
Number of subjects: 533
Study 28099054 — intervention group
Group type: EXPERIMENTAL
Intervention: Noninvasive interventions (e.g., blood cultures, medications, imaging)
Number of subjects: 533
Study 28099054 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive or invasive options (e.g., dialysis, bronchoscopy, surgical consultation, transfer to ICU)
Number of subjects: 533
Study 25853370 — intervention group
Group type: EXPERIMENTAL
Intervention: Methamphetamine (10 mg or 20 mg)
Number of subjects: 19
Study 25853370 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol (0.8 g/kg)
Number of subjects: 19
Study 25853370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in both studies)
Number of subjects: 19
Study 23873217 — intervention group
Group type: EXPERIMENTAL
Intervention: PEG-IFN/RBV
Number of subjects: 474
Study 21723766 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 2901
Study 21723766 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed notification to primary care physicians (alert letter, BMD requisition, and management flowchart)
Number of subjects: 2901
Study 21723766 — intervention group
Group type: EXPERIMENTAL
Intervention: Both physician notifications and patient notification (alert letter)
Number of subjects: 2901
Study 19689979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive aid (poster detailing the NRP algorithm)
Number of subjects: 32
Study 19689979 — intervention group
Group type: COMPARATOR
Intervention: Control (no cognitive aid)
Number of subjects: 32
Study 17116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized classification system for visual field defects
Number of subjects: 189
Study 17116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual fields without adjustment factor
Number of subjects: 189
Study 17116264 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual fields with adjustment factor
Number of subjects: 189
Study 15181049 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg daily for 6 weeks)
Number of subjects: 22
Study 15181049 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 22
Study 10785452 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with HD
Number of subjects: 24
Study 10785452 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls
Number of subjects: 24
Study 9483215 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucocorticoids, mineralocorticoids, and catecholamines
Number of subjects: 110
Study 9483215 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex hormones
Number of subjects: 110
Study 9483215 — intervention group
Group type: EXPERIMENTAL
Intervention: Scirrhous carcinomas
Number of subjects: 110
Study 8141717 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant tissue plasminogen activator (t‐PA)
Number of subjects: 5711
Study 8141717 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 5711
Study 3520315 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydralazine (300 mg per day) and Isosorbide dinitrate (160 mg per day)
Number of subjects: 642
Study 3520315 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (20 mg per day)
Number of subjects: 642
Study 3520315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 642
Study 29861260 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified active treatment with additional mobilization and strength training
Number of subjects: 39
Study 29861260 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 39
Study 27546744 — intervention group
Group type: EXPERIMENTAL
Intervention: AT+rhTM
Number of subjects: 129
Study 27546744 — intervention group
Group type: COMPARATOR
Intervention: AT
Number of subjects: 129
Study 24758169 — intervention group
Group type: EXPERIMENTAL
Intervention: Home group (3‐month SMS reminder and home‐collection)
Number of subjects: 600
Study 24758169 — intervention group
Group type: COMPARATOR
Intervention: Clinic group (3‐month SMS reminder to return to the clinic)
Number of subjects: 600
Study 23230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of low dose (0.5 g) cefozopran hydrochloride
Number of subjects: 24
Study 23230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of middle dose (1.0 g) cefozopran hydrochloride
Number of subjects: 24
Study 23230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of high dose (2.0 g) cefozopran hydrochloride
Number of subjects: 24
Study 23230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple doses (1.0 g) injection of cefozopran hydrochloride
Number of subjects: 24
Study 23230745 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary excretion of cefozopran within 24 h
Number of subjects: 24
Study 21035610 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session group cognitive behavior therapy (CBT)
Number of subjects: 100
Study 21035610 — intervention group
Group type: COMPARATOR
Intervention: Time-matched comparison group condition
Number of subjects: 100
Study 18806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose propofol (3 mg.kg(‐1).h(‐1))
Number of subjects: 150
Study 18806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 microg.kg(‐1).h(‐1))
Number of subjects: 150
Study 18806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (end‐tidal concentration of 0.2%)
Number of subjects: 150
Study 18806051 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 150
Study 18806051 — intervention group
Group type: COMPARATOR
Intervention: Pre-extubation phase
Number of subjects: 150
Study 16104440 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with bupivacaine and pre-incisional intramuscular (IM) ketorolac (group BK)
Number of subjects: 83
Study 16104440 — intervention group
Group type: COMPARATOR
Intervention: Saline local infiltration IM (group NN)
Number of subjects: 83
Study 16104440 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with bupivacaine and saline IM (group BN)
Number of subjects: 83
Study 16104440 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with saline and ketorolac IM (group NK)
Number of subjects: 83
Study 11796545 — intervention group
Group type: EXPERIMENTAL
Intervention: GR79236 (10 microgram/kg)
Number of subjects: 25
Study 11796545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 11796545 — intervention group
Group type: EXPERIMENTAL
Intervention: GR79236
Number of subjects: 25
Study 10048106 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and nutrition education program
Number of subjects: 288
Study 10048106 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 288
Study 7566405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaglobulin (10 g doses at 3-day intervals)
Number of subjects: 71
Study 7566405 — intervention group
Group type: COMPARATOR
Intervention: Placebo (10 g of albumin)
Number of subjects: 71
Study 7566405 — intervention group
Group type: EXPERIMENTAL
Intervention: Gammaglobulin
Number of subjects: 71
Study 7566405 — intervention group
Group type: COMPARATOR
Intervention: Gammaglobulin and Placebo
Number of subjects: 71
Study 1971592 — intervention group
Group type: EXPERIMENTAL
Intervention: Xamoterol
Number of subjects: 0
Study 1971592 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 1971592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenalterol
Number of subjects: 0
Study 1971592 — intervention group
Group type: COMPARATOR
Intervention: ICI 118 551 (control)
Number of subjects: 0
Study 7235737 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral retinoid Ro 10‐9359 (75 mg/d)
Number of subjects: 21
Study 7235737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31129805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 10%
Number of subjects: 64
Study 31129805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 20%
Number of subjects: 64
Study 31129805 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosopis juliflora pods at 30%
Number of subjects: 64
Study 31129805 — intervention group
Group type: COMPARATOR
Intervention: Control diet (no Prosopis juliflora pods)
Number of subjects: 64
Study 27653153 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic Walking training (12-week, 60-minute sessions, 3 times per week)
Number of subjects: 39
Study 27653153 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 25597699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (240 mg)
Number of subjects: 30
Study 25597699 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax ginseng (1200 mg)
Number of subjects: 30
Study 25597699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 24008683 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging (SMS)‐based smoking cessation program
Number of subjects: 0
Study 21832958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) monotherapy
Number of subjects: 150
Study 21832958 — intervention group
Group type: COMPARATOR
Intervention: CNI standard therapy
Number of subjects: 150
Study 19398378 — intervention group
Group type: EXPERIMENTAL
Intervention: Glove electrode TENS (continuous stimulus, 100 Hz, strong but comfortable intensity for 30 minutes)
Number of subjects: 56
Study 19398378 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard electrode TENS (100 Hz for 30 minutes)
Number of subjects: 56
Study 19398378 — intervention group
Group type: COMPARATOR
Intervention: Placebo TENS using a glove electrode (burst stimulus, 100 Hz, 5-second cycle time for 42 seconds, then 0 mA)
Number of subjects: 56
Study 19398378 — intervention group
Group type: COMPARATOR
Intervention: No treatment control
Number of subjects: 56
Study 17907113 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (30-45 mg/day)
Number of subjects: 283
Study 17907113 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide (80-320 mg/day)
Number of subjects: 283
Study 15377582 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 20
Study 15377582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11729367 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside coagulometer (Hemochron) measuring b-APTT
Number of subjects: 20
Study 11729367 — intervention group
Group type: EXPERIMENTAL
Intervention: Duplicate measurements of b-APTT on the Hemochron coagulometer
Number of subjects: 20
Study 11729367 — intervention group
Group type: EXPERIMENTAL
Intervention: APTT ratio of 1.5-2.5
Number of subjects: 20
Study 9530343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aphidicolin (APC) treatment in PHA-stimulated lymphocyte cultures
Number of subjects: 65
Study 9530343 — intervention group
Group type: COMPARATOR
Intervention: Control (no APC treatment)
Number of subjects: 65
Study 8055852 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal vegetarian diet
Number of subjects: 146
Study 8055852 — intervention group
Group type: COMPARATOR
Intervention: Maternal omnivore diet
Number of subjects: 146
Study 8055852 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study 2587826 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent instruction (two sessions per day, random presentation of two words)
Number of subjects: 4
Study 2587826 — intervention group
Group type: COMPARATOR
Intervention: Isolation-intermix instruction (two sessions per day, separate daily sessions for each word followed by random presentation)
Number of subjects: 4
Study 4571196 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate (long-acting phenothiazine)
Number of subjects: 0
Study 4571196 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29229343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed drill with automatic irrigation
Number of subjects: 90
Study 29229343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed drill with manual irrigation
Number of subjects: 90
Study 29229343 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic bone-cutting knife with automatic irrigation (USBCD)
Number of subjects: 90
Study 28166188 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused and Corrective Feedback (FCF)
Number of subjects: 95
Study 28166188 — intervention group
Group type: COMPARATOR
Intervention: Structured and Supported Debriefing (SSD)
Number of subjects: 95